Hepatitis C Treatment One Step At A Time
Download Hepatitis C Treatment One Step At A Time full books in PDF, epub, and Kindle. Read online free Hepatitis C Treatment One Step At A Time ebook anywhere anytime directly on your device. Fast Download speed and no annoying ads. We cannot guarantee that every ebooks is available!
| Author | : National Academies of Sciences, Engineering, and Medicine |
| Publisher | : National Academies Press |
| Total Pages | : 187 |
| Release | : 2016-06-01 |
| Genre | : Medical |
| ISBN | : 0309438020 |
Hepatitis B and C cause most cases of hepatitis in the United States and the world. The two diseases account for about a million deaths a year and 78 percent of world's hepatocellular carcinoma and more than half of all fatal cirrhosis. In 2013 viral hepatitis, of which hepatitis B virus (HBV) and hepatitis C virus (HCV) are the most common types, surpassed HIV and AIDS to become the seventh leading cause of death worldwide. The world now has the tools to prevent hepatitis B and cure hepatitis C. Perfect vaccination could eradicate HBV, but it would take two generations at least. In the meantime, there is no cure for the millions of people already infected. Conversely, there is no vaccine for HCV, but new direct-acting antivirals can cure 95 percent of chronic infections, though these drugs are unlikely to reach all chronically-infected people anytime soon. This report, the first of two, examines the feasibility of hepatitis B and C elimination in the United States and identifies critical success factors. The phase two report will outline a strategy for meeting the elimination goals discussed in this report.
| Author | : Lucinda Porter RN |
| Publisher | : Demos Medical Publishing |
| Total Pages | : 248 |
| Release | : 2013-09-19 |
| Genre | : Health & Fitness |
| ISBN | : 1936303523 |
Hepatitis C Treatment One Step at a Time provides the practical advice and daily inspiration you need to help you successfully complete hepatitis C (HCV) treatment. Deciding to undergo HCV antiviral therapy is one of the bravest and most important steps toward health you'll ever make. As a nurse in the HCV field and a patient who underwent three courses of HCV therapy, Lucinda K. Porter understands how physically and emotionally challenging this experience can be. In Hepatitis C Treatment One Step at a Time, she provides entries for each day of treatment, offering you a daily dose of relief, encouragement, and tips to help you stay on track. From dealing with fatigue and nausea to nosy co-workers and lab results, Porter shows you how to: Prepare mentally, physically, and financially Manage side effects Set up a support system Keep your spirits up Celebrate your strength and acknowledge your milestones Find additional help and up-to-date information with an extensive resources section
| Author | : Lucinda K. Porter, RN |
| Publisher | : Demos Medical Publishing |
| Total Pages | : 248 |
| Release | : 2013-09-19 |
| Genre | : Health & Fitness |
| ISBN | : 1617051748 |
Hepatitis C is the most common blood-borne virus in the U.S. The Centers for Disease Control and Prevention estimate that 3.2 million Americans are chronically infected with the chronic hepatitis C virus (HCV). Treatment for HCV is long, sometimes lasting a year or more with success rate currently around 50%. And the medications often cause incapacitating side effects. Two new medications introduced in 2011 are showing success rates of 75 to 80%. However these new medications are taken with existing HCV drugs and include and intensify the side effects. Hepatitis C Treatment One Step at a Time provides the practical advice and daily inspiration you need to help you successfully make it through hepatitis C (HCV) treatment. Deciding to undergo hepatitis C treatment is one of the bravest and most important steps toward health youíll ever make. As a former Stanford nurse in the HCV field and a patient who was treated twice for HCV, Lucinda K. Porter understands how physically and emotionally challenging treatment can be. In Hepatitis C One Step at a Time, she provides entries for each day of treatment, offering you a daily dose of relief, encouragement, and tips to help you stay on treatment. From dealing with fatigue and nausea to nosy co-workers and lab results, Porter provides everything you need to know to ease the process, including how to: Prepare for treatment, mentally, physically, and financially Manage side effects Set up a support system Keep your spirits up with daily inspiration and humor Celebrate your strength and acknowledge your milestones Find additional community and up-to-date information with an extensive resources section
| Author | : National Academies of Sciences, Engineering, and Medicine |
| Publisher | : National Academies Press |
| Total Pages | : 297 |
| Release | : 2017-07-30 |
| Genre | : Medical |
| ISBN | : 0309457297 |
Hepatitis B and C cause most cases of hepatitis in the United States and the world. The two diseases account for about a million deaths a year and 78 percent of world's hepatocellular carcinoma and more than half of all fatal cirrhosis. In 2013 viral hepatitis, of which hepatitis B virus (HBV) and hepatitis C virus (HCV) are the most common types, surpassed HIV and AIDS to become the seventh leading cause of death worldwide. The world now has the tools to prevent hepatitis B and cure hepatitis C. Perfect vaccination could eradicate HBV, but it would take two generations at least. In the meantime, there is no cure for the millions of people already infected. Conversely, there is no vaccine for HCV, but new direct-acting antivirals can cure 95 percent of chronic infections, though these drugs are unlikely to reach all chronically-infected people anytime soon. This report, the second of two, builds off the conclusions of the first report and outlines a strategy for hepatitis reduction over time and specific actions to achieve them.
| Author | : World Health Organization |
| Publisher | : World Health Organization |
| Total Pages | : 32 |
| Release | : 2021-07-15 |
| Genre | : Medical |
| ISBN | : 924003112X |
WHO has set a global goal to eliminate HCV as a public health problem by 2030. WHO estimates that 58 million people had chronic hepatitis C virus (HCV) infection globally in 2019, and less than a quarter of them were diagnosed. New and innovative approaches are needed to accelerate progress toward the HCV elimination targets. Self-testing is one such approach. These guidelines provide a new recommendation and guidance on HCV self-testing to complement existing HCV testing services in countries. These guidelines also highlight operational considerations to support strategic implementation and scale up of HCV self-testing.
| Author | : World Health Organization |
| Publisher | : World Health Organization |
| Total Pages | : 0 |
| Release | : 2017 |
| Genre | : Medical |
| ISBN | : 9789241549981 |
Testing and diagnosis of hepatitis B (HBV) and C (HCV) infection is the gateway for access to both prevention and treatment services, and is a crucial component of an effective response to the hepatitis epidemic. Early identification of persons with chronic HBV or HCV infection enables them to receive the necessary care and treatment to prevent or delay progression of liver disease. Testing also provides an opportunity to link people to interventions to reduce transmission, through counselling on risk behaviors and provision of prevention commodities (such as sterile needles and syringes) and hepatitis B vaccination. These are the first WHO guidelines on testing for chronic HBV and HCV infection and complement published guidance by WHO on the prevention, care and treatment of chronic hepatitis C and hepatitis B infection. These guidelines outline the public health approach to strengthening and expanding current testing practices for HBV and HCV, and are intended for use across age groups and populations.
| Author | : Mitchell L. Shiffman |
| Publisher | : Springer Science & Business Media |
| Total Pages | : 333 |
| Release | : 2011-11-17 |
| Genre | : Medical |
| ISBN | : 1461411920 |
Chronic Hepatitis C Virus: Lessons from the Past, Promise for the Future documents the monumental advances that have been made in our understanding of chronic HCV during the past decade. The first section reviews the natural history of chronic HCV, how this virus can affect other organs in addition to the liver, and whether treating chronic HCV alters the natural history of this disease. Section 2 reviews the advances that have been made in the treatment of chronic HCV during the past decade with interferon based therapy. Separate chapters on response guided therapy and how to manage the adverse events associated with these medications provide the physician with the concepts required to more effectively treat chronic HCV now and in the future. As the genetics of virologic response have recently been elucidated, a chapter is devoted to helping the clinician understand how genes that modulate disease processes and their treatment are identified and utilized in clinical care. Section 3 deals with the future of HCV treatment and specific inhibitors of HCV. Specific chapters explain how targets for drugs are identified and how drugs are then developed and tested; how mutations of HCV develop and how anti-viral agents will affect this process; the most up to date data regarding the treatment of chronic HCV with peginterferon, ribavirin and anti-viral agents; and the potential to treat chronic HCV with just oral anti-viral agents and without peginterferon and ribavirin in the future. The final section of this book covers issues related to liver transplantation in patients with chronic HCV. Separate chapters review the natural history of chronic HCV in liver transplant recipients and the impact of utilizing HCV positive donors. The volume concludes with chapters that cover the treatment of chronic HCV both prior to and after liver transplantation with potent anti-viral agents. Chronic Hepatitis C Virus: Lessons from the Past, Promise for the Future is a valuable resource for all physicians caring for patients with chronic HCV.
| Author | : Institute of Medicine |
| Publisher | : National Academies Press |
| Total Pages | : 252 |
| Release | : 2010-04-23 |
| Genre | : Medical |
| ISBN | : 0309153689 |
The global epidemic of hepatitis B and C is a serious public health problem. Hepatitis B and C are the major causes of chronic liver disease and liver cancer in the world. In the next 10 years, 150,000 people in the United States will die from liver disease or liver cancer associated with chronic hepatitis B virus (HBV) or hepatitis C virus (HCV) infections. Today, between 800,000 and 1.4 million people in the United States have chronic hepatitis B and between 2.7 and 3.9 million have chronic hepatitis C. People most at risk for hepatitis B and C often are the least likely to have access to medical services. Reducing the rates of illness and death associated with these diseases will require greater awareness and knowledge among health care workers, improved identification of at-risk people, and improved access to medical care. Hepatitis B is a vaccine-preventable disease. Although federal public health officials recommend that all newborns, children, and at-risk adults receive the vaccine, about 46,000 new acute cases of the HBV infection emerge each year, including 1,000 in infants who acquire the infection during birth from their HBV-positive mothers. Unfortunately, there is no vaccine for hepatitis C, which is transmitted by direct exposure to infectious blood. Hepatitis and Liver Cancer identifies missed opportunities related to the prevention and control of HBV and HCV infections. The book presents ways to reduce the numbers of new HBV and HCV infections and the morbidity and mortality related to chronic viral hepatitis. It identifies priorities for research, policy, and action geared toward federal, state, and local public health officials, stakeholder, and advocacy groups and professional organizations.
| Author | : Benoît Rihoux |
| Publisher | : SAGE |
| Total Pages | : 241 |
| Release | : 2009 |
| Genre | : Reference |
| ISBN | : 1412942357 |
This new addition to the Applied Social Research Methods series is unrivalled, it is written by leaders in the growing field of rigorous, comparative techniques.
| Author | : Imran Shahid |
| Publisher | : Bentham Science Publishers |
| Total Pages | : 450 |
| Release | : 2023-01-24 |
| Genre | : Medical |
| ISBN | : 9815123440 |
The burden of hepatitis C virus (HCV) infection on the public health care system continues to remain significant despite the remarkable progress made in HCV therapeutics in the recent past. There are now almost a dozen oral interferon-free direct-acting antivirals available for the treatment of hepatitis C virus infection. Despite advances in the treatment of HCV, therapeutic gaps remain that are yet to be fully explored. Researchers and scientists still strive to understand virus-host interactions to map the disease’s progression along with extrahepatic manifestations and virus invasion strategies impacting the host’s immune system. This book briefly discusses the biology of HCV infection, virus-host interactions, molecular epidemiology of the infection, and the full spectrum of immune responses to hepatitis C. It also provides in-depth information about HCV, clinical diagnostics, and therapeutic knowledge to all stakeholders involved in HCV screening, diagnosis, treatment, and management. Topics covered in the chapters include 1) HCV-host interactions leading to asymptomatic acute infection, 2) the progression of acute HCV infection to chronic disease and subsequent extrahepatic comorbidities, 3) Innate and adaptive immune responses in HCV infections, 4) Consensus-based Approaches for Hepatitis C Screening and Diagnosis, 5) advances in hepatitis C therapy and global management of HCV, and 6) the outcomes of Oral Interferon-free Direct-acting Antivirals as Combination Therapies to Cure Hepatitis C. This book is a valuable addition to undergraduate and postgraduate hepatology students and physicians, clinicians, hepatologists, and health care officials involved in HCV clinical diagnosis and therapeutics.
